ArticleEpidemiology and infection2025
Detection of California Serogroup Orthobunyavirus antibodies and Inkoo virus RNA in patients, Finland.
Article in Epidemiology and infection, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Orthobunyavirus neurovirulence is a complex trait involving all three genome segments.bioRxiv : the preprint server for biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Mosquito-borne California serogroup orthobunyaviruses Inkoo (INKV) and Chatanga (CHATV) are known to be endemic in Finland with a high seroprevalence. We developed a novel multiplexed reverse transcription quantitative polymerase chain reaction method for discriminating between the INKV and CHATV. This assay was used along with traditional serological tests to study a set of summertime patients during the years 2021, 2023, and 2024 to assess the epidemiology and prevalence of acute INKV and CHATV infections in Finland. Altogether, 1470 samples were screened, and there were 16 patients who had an acute infection based on serological findings and/or nucleic acid test. The orthobunyavirus-IgG seroprevalences were 18% (2021), 20% (2023), and 30% (2024), being lower than that in studies from 20 years ago. Neutralization tests were carried out, and all but one acute case had more than four-fold higher titre to INVK vs. CHATV, indicating specificity to INKV infection. The results suggest that epidemiology has changed from previous studies, and INKV should be considered a causative agent of summertime infections in Finland. The symptom diversity in mild disease outcomes should be studied to guide orthobunyavirus recognition by clinicians. The use of molecular assay discriminating INKV and CHATV aids in understanding disease associations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.